average 3 month weight loss on tirzepatide Zepbound Results: First and Beyond average monthly weight loss tirzepatide

Bone health Rapid weight loss can reduce bone density

Sometimes, knowing what triggered your symptoms can help you feel validated

A high-fat diet impairs cardiac high-energy phosphate metabolism and cognitive function in healthy human subjects

FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist ASC35." June 23, 2026

CAS Number: 159649-45-1

Clinical Evidence Supporting Semaglutide Use and Regional Access Considerations Semaglutide, a GLP-1 receptor agonist, has demonstrated weight reduction of 515% in clinical trials and improved cardiovascular outcomes in patients with type 2 diabetes or existing cardiovascular disease